Protein kinase C isozymes as potential therapeutic targets in immune disorders

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Therapeutic Targets

• Publication date

  2008-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14728222.12.5.535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein Kinase C θ Plays a Fundamental Role in Different Types of Chronic Colitis

  2008cited by this paper
• PKC? cooperates with atypical PKC? and PKC? in NF-?B transactivation of T lymphocytes

  2008cited by this paper
• A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

  2008cited by this paper
• Syk inhibitors as treatment for allergic rhinitis.

  2008cited by this paper
• Inactivation of PKCθ leads to increased susceptibility to obesity and dietary insulin resistance in mice

  2007cited by this paper
• The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

  2007cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

  2007cited by this paper
• Muscle-specific knockout of PKC-λ impairs glucose transport and induces metabolic and diabetic syndromes

  2007cited by this paper
• Protein kinase C and other diacylglycerol effectors in cancer

  2007cited by this paper
• Phase I/pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

  2007cited by this paper
• Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

  2007cited by this paper
• The Last 10 Amino Acid Residues beyond the Hydrophobic Motif Are Critical for the Catalytic Competence and Function of Protein Kinase Cα*

  2006cited by this paper
• Resistance to Experimental Autoimmune Encephalomyelitis and Impaired IL-17 Production in Protein Kinase Cθ-Deficient Mice

  2006cited by this paper
• BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism

  2006cited by this paper
• The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

  2006cited by this paper
• Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking.

  2006cited by this paper
• Discontinued drugs in 2005: oncology drugs

  2006cited by this paper
• Trif-related adapter molecule is phosphorylated by PKC{epsilon} during Toll-like receptor 4 signaling.

  2006cited by this paper
• The very C-terminus of protein kinase Cepsilon is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1.

  2006cited by this paper
• Differential roles of PKC-theta in the regulation of intracellular calcium concentration in primary T cells.

  2006cited by this paper
• A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies

  2006cited by this paper
• Trif-related adapter molecule is phosphorylated by PKC during Toll-like receptor 4 signaling

  2006cited by this paper
• Protein kinase C (PKC) family in cancer progression.

  2006cited by this paper
• Peptides Derived from the C2 Domain of Protein Kinase Cϵ (ϵPKC) Modulate ϵPKC Activity and Identify Potential Protein-Protein Interaction Surfaces*

  2006cited by this paper
• Defective IgG2a/2b Class Switching in PKCα−/− Mice1

  2006cited by this paper
• PKC-θ-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis

  2006cited by this paper
• Protein kinase C: novel isozyme-selective peptide inhibitors

  2006cited by this paper
• BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway

  2005cited by this paper
• Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses.

  2005cited by this paper
• Protein Kinase Cθ Controls Th1 Cells in Experimental Autoimmune Encephalomyelitis1

  2005cited by this paper
• B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.

  2005cited by this paper
• BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

  2005cited by this paper
• Identification of an integral plasma membrane pool of protein kinase C in mammalian tissues and cells.

  2005cited by this paper
• The C2 Domain of PKCδ Is a Phosphotyrosine Binding Domain

  2005cited by this paper
• Protein Kinase C (cid:2) Is Not Essential for T-Cell-Mediated Clearance of Murine Gammaherpesvirus 68

  2005cited by this paper
• Protein Kinase C-θ Is an Early Survival Factor Required for Differentiation of Effector CD8+ T Cells1

  2005cited by this paper
• Control of T helper 2 cell function and allergic airway inflammation by PKCzeta.

  2005cited by this paper
• A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

  2005cited by this paper
• PKCθ Signals Activation versus Tolerance In Vivo

  2004cited by this paper
• Protein Kinase C (cid:2) Is Critical for the Development of In Vivo T Helper (Th)2 Cell But Not Th1 Cell Responses

  2004cited by this paper
• PKC at a glance

  2004influential reference
• Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation.

  2004cited by this paper
• B Cell-Activating Factor Belonging to the TNF Family Acts through Separate Receptors to Support B Cell Survival and T Cell-Independent Antibody Formation

  2004cited by this paper
• Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells

  2004cited by this paper
• Differential Regulation of Th2 and Th1 Lung Inflammatory Responses by Protein Kinase Cθ1

  2004cited by this paper
• Catalytic Domain Crystal Structure of Protein Kinase C-θ (PKCθ)*♦

  2004cited by this paper
• Positive feedback regulation of PLCγ1/Ca2+ signaling by PKCθ in restimulated T cells via a Tec kinase‐dependent pathway

  2004cited by this paper
• SPAK kinase is a substrate and target of PKCθ in T‐cell receptor‐induced AP‐1 activation pathway

  2004cited by this paper
• PKC-θ knockout mice are protected from fat-induced insulin resistance

  2004cited by this paper
• Regulation of B-cell survival by BAFF-dependent PKCδ-mediated nuclear signalling

  2004influential reference
• Induction of arthritis by single monoclonal IgG anti‐collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB

  2003cited by this paper
• Kinases as therapeutic targets for heart failure

  2003cited by this paper
• Protein Kinase C (PKC) Acts Upstream of PKC To Activate IB Kinase and NF-B in T Lymphocytes

  2003cited by this paper
• Early Studies of Protein Kinase C

  2003cited by this paper
• PKC zeta participates in activation of inflammatory response induced by enteropathogenic E. coli.

  2003cited by this paper
• Increased skeletal muscle expression of PKC‐θ but not PKC‐α mRNA in type 2 diabetes: inverse relationship with in‐vivo insulin sensitivity

  2003cited by this paper
• A Ras activation pathway dependent on Syk phosphorylation of protein kinase C

  2003cited by this paper
• Essential role of RelA Ser311 phosphorylation by ζPKC in NF‐κB transcriptional activation

  2003cited by this paper
• Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes.

  2003cited by this paper
• Early studies of protein kinase C: a historical perspective.

  2003cited by this paper
• Protein Kinase C (cid:2) Affects Ca 2 (cid:3) Mobilization and NFAT Cell Activation in Primary Mouse T Cells

  2003influential reference
• Transgenic mice with dominant negative PKC‐theta in skeletal muscle: A new model of insulin resistance and obesity

  2003cited by this paper
• Protein Kinase C- (cid:2) Is a Negative Regulator of Antigen-Induced Mast Cell Degranulation

  2002cited by this paper
• WIP deficiency reveals a differential role for WIP and the actin cytoskeleton in T and B cell activation.

  2002cited by this paper
• Translocation of PKCθ in T cells is mediated by a nonconventional, PI3-K– and Vav-dependent pathway, but does not absolutely require phospholipase C

  2002cited by this paper
• Beta phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs.

  2002cited by this paper
• A requirement for CARMA1 in TCR-induced NF-κB activation

  2002cited by this paper
• Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation.

  2002cited by this paper
• Protein kinase Cδ controls self-antigen-induced B-cell tolerance

  2002cited by this paper
• A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study

  2002cited by this paper
• Critical role of protein kinase C ϵ for lipopolysaccharide‐induced IL‐12 synthesis in monocyte‐derived dendritic cells

  2002cited by this paper
• PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling

  2002cited by this paper
• CARMA1 is a critical lipid raft–associated regulator of TCR-induced NF-κB activation

  2002cited by this paper
• Role of ζPKC in B‐cell signaling and function

  2002cited by this paper
• Protein kinase C inhibitors

  2002cited by this paper
• Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ

  2002cited by this paper
• Protein Kinase C (cid:2) Controls Nuclear Factor (cid:3) B Activation in B Cells Through Selective Regulation of the I (cid:3) B Kinase (cid:4)

  2002cited by this paper
• Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

  2002cited by this paper
• Antigen-induced translocation of PKC-θ to membrane rafts is required for T cell activation

  2001cited by this paper
• Protein Kinase C: Structural and Spatial Regulation by Phosphorylation, Cofactors, and Macromolecular Interactions

  2001cited by this paper
• A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

  2001cited by this paper
• Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

  2001cited by this paper
• Structure of the C2 domain from novel protein kinase Cepsilon. A membrane binding model for Ca(2+)-independent C2 domains.

  2001cited by this paper
• Protein Kinase C (cid:2) Is Required for Macrophage Activation and Defense Against Bacterial Infection

  2001cited by this paper
• Phase II evaluation of bryostatin-1 in metastatic melanoma

  2001cited by this paper
• ZAP-70 and SLP-76 Regulate Protein Kinase C-θ and NF-κB Activation in Response to Engagement of CD3 and CD28

  2001cited by this paper
• Regulation of Protein Kinase Cθ Function during T Cell Activation by Lck-mediated Tyrosine Phosphorylation*

  2000cited by this paper
• PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes

  2000influential reference
• T cell expressed PKCθ demonstrates cell‐type selective function

  2000cited by this paper
• Protein kinase C binding partners.

  2000cited by this paper
• Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta.

  2000cited by this paper
• Results of an exploratory phase ii study on a protein kinase C inhibitor in low grade lymphoproliferative disorders

  1998cited by this paper
• Three-dimensional segregation of supramolecular activation clusters in T cells

  1998cited by this paper
• B cell‐deficient mice do not develop type II collagen‐induced arthritis (CIA)

  1998cited by this paper
• NMR structure of a protein kinase C-gamma phorbol-binding domain and study of protein-lipid micelle interactions.

  1997cited by this paper
• Selective modulation of protein kinase C-Θ during T-cell activation

  1997cited by this paper
• Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

  1996cited by this paper
• Immunodeficiency in Protein Kinase Cβ-Deficient Mice

  1996cited by this paper
• Anti-inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C.

  1995cited by this paper
• Phosphorylation of the gamma chain of the high affinity receptor for immunoglobulin E by receptor-associated protein kinase C-delta.

  1994cited by this paper

• Pharmacophore modeling, docking and molecular dynamics simulation for identification of novel human protein kinase C beta (PKCβ) inhibitors

  2022cites this paper
• Developmental protein kinase C hyper-activation results in microcephaly and behavioral abnormalities in zebrafish

  2018cites this paper
• Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β.

  2017cites this paper
• Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example.

  2014cites this paper
• Two faces of inflammation: an immunopharmacological view.

  2014cites this paper
• Protein Kinase C Overexpression Does Not Enhance Immune-Stimulatory Surface Markers of Vaccinia-Infected Dendritic Cells and DC Cell Lines

  2013cites this paper
• A unified approach to the important protein kinase inhibitor balanol and a proposed analogue

  2013cites this paper
• Notch and PKC Are Involved in Formation of the Lateral Region of the Dorso-Ventral Axis in Drosophila Embryos

  2013cites this paper
• 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.

  2011cites this paper
• Phorbol Esters and Diacylglycerol: The PKC Activators

  2010cites this paper
• The use of differential receptors to pattern peptide phosphorylation.

  2009cites this paper